Business
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice
Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA
About this update from Caredx, Inc.
[{"type":"text","content":"\nGuide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monitoring protocol in clinical practice.\n\nThe publication1 reviews the clinical evidence for noninvasive surveillance, much of which evaluates the multicenter study data demonstrating the clinical utility of AlloMap® gene-expression profiling (GEP) and AlloSure® donor-derived cell-free DNA (dd-cfDNA). The authors also discuss the complementary role of GEP and dd-cfDNA and review the data suggesting that the tests can be used together for effective noninvasive rejection surveillance in heart transplant patients.\n\n“CareDx is very proud to have helped clinicians shift their reliance on invasive EMBs to non-invasive solutions for routine heart transplant surveillance. We’ve led the way by delivering an extensive body of clinical evidence in support of our HeartCare® testing services, AlloMap and AlloSure,” said Reg Seeto, CEO and President of CareDx. “I am delighted to see the publication of the JACC: Heart Failure guide on the heels of the new International Society for Heart and Lung Transplantation guidelines2 that support the routine use of both GEP and dd-cfDNA.”\n\nKey Highlights:\n\n\nRejection surveillance using GEP and dd-cfDNA, such as AlloMap and AlloSure is noninferior to endomyocardial biopsy.\n\n\nThe use of multimodal solutions including GEP to assess immune quiescence and dd-cfDNA to identify graft injury, offers a robust strategy for the surveillance of heart transplant recipients.\n\n\nAlloSure and AlloMap have been tested and validated for acute rejection surveillance in numerous multicenter studies.\n\n\nNon-invasive surveillance indicators of rejection can precede pathological rejection diagnosis.\n\n\n“Much innovation has occurred over the past decade and there is str...